To investigate transcription factor PAX5 expression characteristics in childhood acute leukemic cells, expression levels of PAX5 and CD19 mRNA in 6 hematological tumor cell lines and bone marrow cells of 6 normal children, 58 de novo patients and 4 relapse acute leukemic children, including 39 cases of B-ALL,10 cases of T-ALL and 13 cases of AML, were detected by a real-time RT-PCR.
Methods: The psychological status of 52 children with hematological tumor and their parents, and 48 healthy children and their parents were measured by means of the self-compiled psychological status scale and the symptom checklist 90 (SCL-90).
This study is to determine whether induction high dose EPO followed by weekly maintenance usage could improve hemoglobin (Hb) levels in anemic hematological malignancy patients receiving chemotherapy. Methods The open-label, nonrandomized clinical study evaluated the response rate of induction EPO 120,000 U (40,000 U SC d1、d3、d5) followed by maintenance dose of 40,000 U SC once weekly for 3 weeks (d8、d15、d22).
Methylcillin resistant coagulase negative staphylococcus (MRCNS) was the most prevalent Gram (+) bacteria in the complicated infection patients with hematological malignancies, which accounted for 88.5%.
Objective To study the effect of recombinant human granulocyte colony-stimulating factor(rhG-CSF) on neutrophil function in patients with hematological malignancies receiving chemotherapy.
GPⅤ were 69.99%,10%,20% and 0% in ITP, CAA, hematologic malignancy group and healthy volunteers respectively. There was significant difference between ITP and CAA (χ 2=20.71, P<0.005), between ITP and hematologic malignancy group (χ 2=12.22, P<0. 005).
Objective To study the changes of serum lactate dehydrogenase(LDH) in hematologic malignancy group and complete remission(CR) group,as well as its prognostic clinical singnificance.
The CR group had no significant difference than the control group (P>0.05),when these hematologic malignancy relapsed,the serum LDH level increased obviously again.
Recently angiogenesis induction was described in several hematologic neoplasms as leukemia, lymphoma, myelodysplastic syndrome and multiple myeloma (MM).
Development of antiangiogenic treatment for hematologic neoplasms has recently been sparked by the success of Thalidomide (Thal) which has antiangiogenic properties in MM.
Antiangiogenic treatment strategies are now being tested in clinical trials on several types of hematologic neoplasms.
Pathomorphological examination of trephine biopsies of the bone marrow (BM) represents a standard method for the diagnosis and staging of hematologic neoplasms and other disorders involving the BM.
The increasing knowledge about the genetic basis and biology of hematologic neoplasms, as well as the recently proposed WHO classification system, provide the framework for an accurate diagnosis.
The hospital mortality for mechanically ventilated patients ranges from 70-90% in patients with solid tumors to 75-90% in patients with hematological malignancy and up to 95% in patients after bone marrow transplantation.
From these 94 cancer patients, 64 patients had a hematological malignancy, while 30 patients had a solid tumor.
Hematological malignancy maybe the most susceptible confluence of HGV.
Noninvasive continuous positive airway pressure delivered by helmet in hematological malignancy patients with hypoxemic acute re
Changes in severity and organ failure scores as prognostic factors in onco-hematological malignancy patients admitted to the ICU
Emerging evidence suggests that angiogenesis may play an important role in hematological malignancies, such as leukemia.
aeruginosa was more frequently isolated from patients with hematological malignancies and MRSA with solid tumors.
Endotoxemia in febrile patients with hematological malignancies.
The relation between gram-negative bacteremia, endotoxemia and cytokinemia in patients with hematological malignancies was studied.
Serum endotoxin and cytokines (tumor necrosis factor-α, interleukin-1 receptor antagonist, interferon-γ, interleukin-6 and interleukin-10) were determined in 24 patients with hematological malignancies.